

ABSTRACT

The present invention relates to novel, non-secosteroidal, hydroxyl substituted, carbon-linked diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1,25 dihydroxy vitamin D₃. These compounds are useful for treating bone disease and psoriasis.

X-15628

--